Navigation Links
'Study of Studies' Finds No Risk to Children From Phthalates in Toys
Date:9/4/2007

Comprehensive Review of Scientific Research Dismisses Rationale for Proposed California Toy Ban

SACRAMENTO, Calif., Sept. 4 /PRNewswire-USNewswire/ -- An exhaustive study analyzing years of scientific research has conclusively determined that a type of chemical targeted for a ban poses no risk to children when it is used in toys, according to a report released today.

Officials from the Toy Industry Association (TIA), which commissioned the report, said it disproved any justification for Assembly Bill 1108 (Ma).

Currently pending in the California Legislature, the bill seeks to ban toys using di-isononyl phthalates (DINP), the principal ingredient used to make vinyl toys soft, thereby helping reduce or eliminate potential choking hazards.

"Although well intentioned, AB 1108 is based on a contrived problem that does not exist according to the weight of international science," said Joan Lawrence, TIA's Vice President for Safety Standards and Regulatory Affairs.

"Toy safety is TIA's number one priority and we have supported the development of stringent toy safety standards throughout the world," she said. "But after exhaustive research and a thorough review of multiple international studies it is clear that toys containing DINP do not pose a risk to children's health."

The independently conducted report reviewed more than 140 separate scientific papers, studies and research documents investigating "phthalates." The analysis looked at a wide body of scientific evidence, including studies promoted by AB 1108 supporters, as well as research conducted in Japan, the Netherlands, Canada, the European Union and by a wide range of U.S. environmental and consumer agencies.

Exponent, a nationally renowned consulting firm made up of scientists, physicians, engineers, and regulatory experts who perform in-depth scientific research and analysis, conducted the study.

A summary of its 69-page report, Review and Risk Analysis of Child Exposure to Di-Isononyl Phthalate in Toys, found that:

-- "There was no data identified that support the occurrence of

developmental toxicity from DINP in humans." In other words, no

negative effects on the human reproductive system were found.

-- The U.S. Consumer Product Safety Commission and other regulatory

agencies have repeatedly determined that DINP can be safely used in

children's toys, despite the fact that they "overestimated" the

actual amount of exposure children might have to DINP products.

-- Overall, the assessments "conclude that the current exposure of

children to DINP-containing toys would pose a minimal to nonexistent

risk of health effect."

"We commissioned this study out of an abundance of caution and as a way of taking a step back to triple-check all the research performed to date," said TIA's Lawrence. "Was there any new information? Was anything missed that would signal a legitimate risk posed by DINP? Fortunately, the answers echo previous findings that toys containing DINP are safe for children."

Based on the research, Lawrence reiterated TIA's strong opposition to AB 1108.

"There are certainly real safety and inspection issues that warrant thoughtful policy debate, but the safety of DINP is not one of them," she said.

More information may be found at http://www.toy-tia.org. News reporters should contact Stevan Allen at (916) 448-1336 or stevan@allenstrategic.com for more information, to obtain the Exponent report or to arrange interviews.


'/>"/>
SOURCE Toy Industry Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... 2017 , ... SignatureCare Emergency Center – South Austin is treating both adult ... day. , The Emergency Room opened early March, making it the ... now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical ...
(Date:7/24/2017)... ... July 24, 2017 , ... ...      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, ... celebrate the structural topping out of the new Destination Medical Building located ...
(Date:7/24/2017)... ... ... SignatureCare Emergency Center is looking to award their 2017 Fall Scholarship. ... student. Get your applications in now as the deadline is approaching fast. ... a nursing student at Prairie View A&M University with a 3.45 GPA. Castillo was ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services has ... Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. The ... facilitate the development of a hub and spoke model for opioid treatment in ...
(Date:7/24/2017)... ... July 24, 2017 , ... A ... destroyed the construction site and threatened numerous homes and businesses nearby, causing some ... on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. notes ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... -- New York City-based market research firm Kalorama Information notes seven ... From new products to new costs, to the threat of ... study, Potential Pipeline Disruptors . Among them ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... the growing population and, to a more extreme extent, the ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
Breaking Medicine Technology: